An expanding knowledge of the underlying molecular biology of ccRCC, which is dominated by mutations and/or loss of pVHL leading to constitutive stabilization of the HIF transcription factors and expression of a host of target genes, has led to the successful development of several lines of targeted therapeutics. The gene discussed is VHL; the disease is nonpapillary renal cell carcinoma.